Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | TOP2A | P11388 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3957731 | 0.90 | SRC (0.31) | — | |
| SCHEMBL13906785 | 0.90 | ADORA2A (0.33) | ADORA2A | |
| SCHEMBL3952292 | 0.90 | ADORA2A (0.33) | ADORA2A | |
| SCHEMBL3947881 | 0.89 | ADORA2A (0.39) | ADORA2ATOP2A | |
| SCHEMBL3957754 | 0.88 | ADORA2A (0.39) | ADORA2A | |
| SCHEMBL13906745 | 0.88 | ADORA2A (0.39) | ADORA2A | |
| SCHEMBL3947368 | 0.87 | METTL3 (0.32) | — | |
| SCHEMBL3949217 | 0.83 | CTSB (0.32) | ADORA2A | |
| SCHEMBL3950330 | 0.83 | SRC (0.31) | — | |
| SCHEMBL3949379 | 0.82 | ADORA2A (0.32) | ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009029729-A1 | AMINO TRICYCLIC-NUCLEOSIDE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GENELABS TECHNOLOGIES, INC. (US) | 2009-03-05 | — | — | WO | disclosed |
| US-20090062223-A1 | AMINO TRICYCLIC-NUCLEOSIDE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GENELABS TECHNOLOGIES, INC. | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062223-A1 | AMINO TRICYCLIC-NUCLEOSIDE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | PNP, SLC29A1, SLC28A1 | ADORA2A 277/4885TOP2A 1253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.